UniPharma Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Yu-Shan Wang

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	geen gegevens

Recente managementupdates

Recent updates

CEO

Yu-Shan Wang

no data

Tenure

Yu-Shan Wang, Ph D., is General Manager of UniPharma Co., Ltd. Educations Doctor of Philosophy, Cancer Research Center, Department of Veterinary Medicine, National Taiwan University, Taipei, Taiwa...

UniPharma Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

UniPharma Co., Ltd., Annual General Meeting, Jun 25, 2024

UniPharma Co., Ltd., Annual General Meeting, Jun 21, 2022

Recent updates

New major risk - Share price stability

Full year 2023 earnings released: NT$0.61 loss per share (vs NT$0.18 loss in FY 2022)

Full year 2023 earnings released: NT$0.61 loss per share (vs NT$0.18 loss in FY 2022)

UniPharma Co., Ltd., Annual General Meeting, Jun 25, 2024

New minor risk - Financial data availability

New minor risk - Share price stability

Full year 2022 earnings released: NT$0.18 loss per share (vs NT$2.11 loss in FY 2021)

First half 2022 earnings released: EPS: NT$0.07 (vs NT$0.61 loss in 1H 2021)

Full year 2021 earnings released: NT$2.11 loss per share (vs NT$1.57 loss in FY 2020)

UniPharma Co., Ltd., Annual General Meeting, Jun 21, 2022

Full year 2020 earnings released: NT$1.57 loss per share (vs NT$0.71 loss in FY 2019)

New 90-day low: NT$11.80

New 90-day low: NT$14.90

New 90-day low: NT$15.95

New 90-day low: NT$16.35

First half earnings released

CEO

Tenure